AGTC:NSD-Applied Genetic Technologies Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.08

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

1.87M

Average Target Price

USD 13.00 (+155.91%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida. Address: 14193 NW 119th Terrace, Alachua, FL, United States, 32615

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.25B 20.66 14.64
REGN Regeneron Pharmaceuticals, Inc

N/A

USD48.27B 14.76 12.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

N/A

USD29.06B N/A N/A
RPRX Royalty Pharma plc

N/A

USD28.27B 22.60 14.17
SGEN Seagen Inc

N/A

USD27.38B 44.84 41.48
BNTX BioNTech SE

N/A

USD26.25B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AGTC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.21% 66% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.21% 66% D 75% C
Trailing 12 Months  
Capital Gain 7.40% 36% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.40% 36% F 32% F
Trailing 5 Years  
Capital Gain -63.64% 24% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.64% 24% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -7.06% 30% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.06% 30% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 51.10% 55% F 27% F
Risk Adjusted Return -13.82% 31% F 25% F
Market Capitalization 0.22B 34% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.38 26% F 30% F
Price/Book Ratio 5.22 55% F 36% F
Price / Cash Flow Ratio -5.21 35% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -111.33% 24% F 10% F
Return on Invested Capital -59.00% 50% F 16% F
Return on Assets -45.55% 20% F 6% F
Debt to Equity Ratio 13.63% 54% F 72% C-
Technical Ratios  
Short Ratio 0.47 78% C+ 75% C
Short Percent 3.82% 67% D+ 45% F
Beta 2.24 15% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector